

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.     (Original)    A pharmaceutical composition comprising
  - i)     one or more purified flavonoids; and
  - ii)    purified menthol; and
  - iii)   pharmaceutically acceptable exipients.
  
2.     (Original)    The pharmaceutical composition according to claim 1, wherein said composition essentially consists of
  - i)     one or more purified flavonoids; and
  - ii)    purified menthol; and
  - iii)   pharmaceutically acceptable exipients, wherein said exipients are not therapeutically active.
  
3.     (Original)    The pharmaceutical composition according to claim 1, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.
  
4.     (Original)    The pharmaceutical composition according to claim 3, wherein said composition essentially consists of

- i) one or more purified flavonoids; and
  - ii) purified menthol; and
  - iii) one or more metal complexes and/or metal salts; and
  - iv) pharmaceutically acceptable expients, wherein said expients are not therapeutically active.
5. (Currently amended) The pharmaceutical composition according to ~~any of claims 3 and 4~~, wherein said metal is zinc.
6. (Currently amended) The pharmaceutical composition according to ~~any of claims 3 and 4~~, wherein the metal is zinc selected from the group consisting of  $\text{Zn}^{2+}$  aminochelates ,  $\text{Zn}^{2+}$  amino acid chelates,  $\text{Zn}(\text{acetate})_2$ ,  $\text{Zn}^{2+}$  DL-methionine,  $\text{Zn}^{2+}$  L-methionine, ZnGluconate and PolaPreZinc ®.
7. (Original) The pharmaceutical composition according to claim 1, wherein said composition is useful for oral and/or nasal administration.
8. (Original) The pharmaceutical composition according to claim 1, wherein said composition is selected from the group consisting of lozenges, troches, capsules, syrups, tablets, lollipops, solutions, dispersions, suspensions, powders,


microspheres,        chewing tablets,    chewing gums,    sprays,  
droppers, pipettes and pills.

9. (Original)    The pharmaceutical composition according to claim 1, wherein said composition is a slow-release composition.
10. (Original)    The pharmaceutical composition according to claim 1, wherein said composition is lozenges.
11. (Original)    The pharmaceutical composition according to claim 1, wherein said composition is essentially free of crude plant extracts.
12. (Original)    The pharmaceutical composition according to claim 1, wherein said composition is essentially free of other terpenes than menthol.
13. (Original)    The pharmaceutical composition according to claim 1, wherein said composition is essentially free of one or more selected from the group consisting of menthone, menthyl acetate, limonene and neomenthol.
14. (Original)    The pharmaceutical composition according to


claim 1, wherein one or more flavonoids are chelating a metal.

15. (Original)    The pharmaceutical composition according to claim 1, wherein the metal is  $\text{Zn}^{2+}$ .

16. (Original)    The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of flavonoids of the general formula:



and the general formula:



In re of: 10/532,341    BERG3

Wherein

R2' can be selected from:

-H

-OH

R3' can be selected from:

-H

-OH

-OCH<sub>3</sub>

-OCH<sub>2</sub>CH<sub>2</sub>OH

R4' can be selected from:

-H

-OH

-OCH<sub>3</sub>

-OCH<sub>2</sub>CH<sub>2</sub>OH

R5' can be selected from:

-H

-OH

-OCH<sub>3</sub>

-OCH<sub>2</sub>CH<sub>2</sub>OH

R6' is -H;

R3 including R3<sub>1</sub> and R3<sub>2</sub> can individually be selected from:

- H
- OH
- O-rutinoside
- O-glucoside
- O-glucose-p-coumaric acid
- SOH
- O-rhamnose

R4 can be selected from:

- (O)
- OH

R5 can be selected from:

- H
- OH
- O-CH<sub>2</sub>CH<sub>2</sub>OH

R6 can be selected from:

- H
- OH
- OCH<sub>3</sub>

R7 can be selected from:

- H
- OH
- O-glucose

-OCH<sub>3</sub>  
-OCH<sub>2</sub>CH<sub>2</sub>OH  
-O-glucuronic acid  
-O-rutinose  
-O-rhamnoglucoside

R8 can be selected from:      -H  
   -OH

17. (Original)      The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of troxerutin, venoruton, hesperitin, naringenin, nobiletin, tangeritin, baicalein, galangin, genistein, quercetin, apigenin, kaempferol, fisetin, rutin, luteolin, chrysin, taxifolin, eriodictol, catechitin, epicatechin gallate, epigallocatechin gallate, flavone, sideritoflavone, hypolaetin-8-O-Gl, oroxindin, 3-hydroxyflavone, morin, quercetagenin-7-O-Gl, tambuletin, gossypin, hipifolin, naringin, leucocyanidol, amentoflavone and derivatives thereof and mixtures thereof

18. (Original)      The pharmaceutical composition according to claim 1, wherein said flavonoid is not a naturally occurring flavonoid.

19. (Original)     The pharmaceutical composition according to claim 1, wherein said flavonoid is a rutoside.
20. (Original)     The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a rutoside aglycone.
21. (Original)     The pharmaceutical composition according to claim 1, wherein said flavonoid is a hydroxyethylrutoside.
22. (Original)     The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a hydroxyethylrutoside aglycone.
23. (Original)     The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of hydroxyethylrutosides.
24. (Original)     The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of mono-, di-, tri- and tetrahydroxyethylrutosides.
25. (Original)     The pharmaceutical composition according to



claim 1, wherein at least one flavonoid is troxerutin.

26. (Original)     The pharmaceutical composition according to claim 1, where at least one flavonoid is troxerutin aglycone.

27. (Original)     The pharmaceutical composition according to claim 1, wherein the flavonoid is veneruton.

28.-57. (Cancelled)

58. (Currently amended) A method of treatment of a clinical condition or symptoms of a clinical condition in an individual in need thereof, comprising administering to said individual the pharmaceutical composition according to ~~any~~ ~~of~~ claims 1 ~~to~~ 27.

59. (Original)     The method according to claim 58, wherein said clinical condition is a condition relating to common cold.

60. (Original)     The method according to claim 58, wherein the clinical condition is common cold of the upper and/or lower respiratory tract and/or eyes.

61. (Original)    The method according to claim 59, wherein the conditions relating to common cold are viral infections of the upper and/or lower respiratory tract and/or eyes.
62. (Original)    The method according to claim 59, wherein the conditions relating to common cold are bacterial infections of the upper and/or lower respiratory tract and/or eyes.
63. (Original)    The method according to claim 59, wherein the conditions relating to common cold are allergic conditions of the upper and/or lower respiratory tract and/or eyes.
64. (Original)    The method according to claim 59, wherein the conditions relating to common cold are characterized by one or more symptoms of the group comprising coughing, sneezing, muscle pain, sore throat, irritated throat, hoarseness, headache, malaise, chilliness, fever, nasal discharge, nasal obstruction, pain relating to the sinuses, rhinitis, swelling of mucosal membranes, pharyngitis, asthma, and bronchitis.
65. (Original)    The method according to claim 59, wherein the condition relating to common cold is a viral infection caused by or associated with one or more viruses selected

from the group consisting of adenoviruses, parvoviruses, picornaviruses, reoviruses, orthomyxoviruses, paramyxoviruses, arenaviruses, caliciviruses, coronaviruses, orthomyxoviruses, rhinovirus, influenza virus, including influenza virus type A and B, echovirus and coxsackie virus.

66. (Original)     The method according to claim 59, wherein the condition relating to common cold is a viral infection caused by or associated with one or more viruses selected from the group consisting of coronaviruses and rhinoviruses.

67. (Original)     The method according to claim 59, wherein the condition relating to common cold is a bacterial infection caused by or associated with one or more bacteria selected from the group consisting of *Streptococcus pneumoniae*,, *Streptococcus Haemolyticae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*.

68. (Original)     The method according to claim 59, wherein the condition relating to common cold is an allergic condition selected from the group consisting of rhinitis, acute and chronic bronchitis and hay fever.

69. (Original)     The method according to claim 59, wherein the

condition related to common cold is an allergic condition characterised by one or more symptoms selected from the group consisting of nasal discharge, nasal congestion, sneezing, cough, swelling of mucosal membranes and rhinitis.

70. (Original) The method according to claim 58, wherein the administration is to the mucosal membrane of the upper and/or lower respiratory tract and/or of the eyes.

71. (Original) The method according to claim 58, wherein the administration is topical to the mucosal membrane of the oral cavity.

72.-73. (Cancelled)

✓74. (Original) A method of reducing the amount of virus in a composition, comprising incubating said composition comprising virus with menthol.

75. (Original) The method according to claim 74, wherein said virus is rhinovirus.

76. (Original) A method of reducing the amount of virus in an individual infection with said virus, comprising

administering to said individual a pharmaceutical composition comprising menthol, thereby reducing the amount of said virus in said individual.

77. (Original) The method according to claim 76, wherein said virus is rhinovirus.

78. (Original) The method according to claim 76, wherein the method further comprises administering at least one flavonoid to said individual.

79.- 80. (Cancelled)

81. (New) The method according to claim 58, wherein said flavonoid is a hydroxyethylrutoside.

82. (New) The method according to claim 58, wherein at least one flavonoid is troxerutin.

83. (New) The method according to claim 58, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.